The GLAUrious project is clinically testing and validating the novel External Automatic Glaucoma Laser (EAGLE) device developed and patented by BELKIN Laser Ltd with the goal of providing accessible first-line treatment for glaucoma. About 64 million people worldwide suffer from glaucoma, which is a chronic disease causing progressive optic nerve degeneration, is the leading cause of irreversible blindness globally. Although incurable, disease progression can be arrested or delayed by reducing the pressure inside the eye, thus preventing visual incapacitation and blindness.
Current first-line treatment requires life-long daily eye drops, a strict regimen causing 50% patient dropout after 1 year.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement